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Are North American Bunyamwera Serogroup Viruses
Etiologic Agents of Human Congenital Defects of the
Central Nervous System?
In 1941 Gregg provided the first evidence that
rubella virus (family Togaviridae, genus Ru-
bivirus) causes human congenital defects (1). Al-
though rubella virus infection usually causes a
mild disease comprising fever and rash, rubella
epidemics have been associated with congenital
defects in children of women who became infected
during their first trimester of pregnancy (2). The
risk of in utero rubella infection was reduced by
the introduction of safe and effective vaccines for
women of child-bearing age. Congenital abnor-
malities in fetal or neonatal ruminants also are
related to exposure of pregnant dams to various
viruses, including bovine viral diarrhea virus
(family  Togaviridae, genus Pestivirus), the arthro-
pod-borne bluetongue viruses (family Reoviridae,
genus Orbivirus), Wesselsbron virus (family
Flaviviridae, genus Flavivirus), Rift Valley fever
virus (family Bunyaviridae, genus Phlebovirus),
Nairobi sheep disease virus (family Bunyaviridae,
genus Nairovirus), and Akabane and Aino (family
Bunyaviridae, genus Bunyavirus, Simbu sero-
group) viruses (3-10). Infections of livestock with
these viruses may produce low-titer viremia with
no apparent clinical disease, or high-titer viremia
and severe clinical illness in the dam.  In utero
infections may result in malformations of the de-
veloping fetus, fetal death with resorption, mum-
mification, or miscarriage. Stillborn ruminants
may show various musculoskeletal and central
nervous system defects, including a syndrome of
arthrogryposis with hydranencephaly (AGH).
Bunyamwera serogroup viruses (family Bun-
yaviridae, genus Bunyavirus) have been isolated
from humans, and some, including Cache Valley
(CV) and Tensaw (TEN) viruses, have been iso-
lated from symptomatic and asymptomatic large
mammals (11). Antibodies to CV virus and other
viruses of the Bunyamwera serogroup are preva-
lent in livestock and large wild mammals and in
humans in the Western Hemisphere from Alaska
to Argentina (11). Viruses of this serogroup are
isolated primarily from mosquitoes of the genera
Aedes and Anopheles. These viruses have focal
geographic distributions, although some are found
over great expanses. CV virus, a common North
American bunyavirus, has been isolated
principally from mosquitoes of the genera Cu-
liseta, Aedes, and Anopheles. The geographic dis-
tribution of this virus includes all North America,
except the extreme southeastern states and south-
ern Mexico (11). In the southeastern United
States, TEN virus, also isolated from mosquitoes
of the genera Anopheles and Aedes, is the only
known representative of the Bunyamwera sero-
group, probably because of the range of the prin-
cipal vectors and vertebrate hosts; mutual
exclusion of these two viruses likely occurs be-
cause of cross-protectivity between them (12).
Serologic and temporal associations of infection
with CV virus and congenital malformations, in-
cluding primarily AGH, were observed in sheep
near San Angelo, Texas, between December 1986
and February 1987, suggesting that this virus
causes AGH (13). Subsequent outbreaks of similar
congenital defects occurred in sheep in Illinois in
1988 (J. Pearson, pers. comm.) and in North Da-
kota, Pennsylvania, Maryland, Michigan, and Ne-
braska in 1986 and 1987 (14). Antibody to CV virus
(but not to other viruses) was found to correlate
significantly with the occurrence of AGH and other
congenital anomalies during the Texas outbreak
(15, 16), and IgM antibody to CV virus was de-
tected in colostrum-free neonates with AGH (C.H.
Calisher, unpublished data). (Neither maternal
IgM nor maternal IgG crosses the placenta in
sheep; therefore, antibody in fetuses or in neo-
nates before they received colostrum indicates fe-
tal exposure to an infectious agent [17].)
In 1976, antibody to CV virus was detected in
serum from cattle that had delivered calves with
AGH in Saskatchewan, Canada, in 1975; however,
the prevalence of antibodies to CV virus in the
bovine population of that area was not investi-
gated (R.E. Shope, pers. comm.). In Texas, in 1981,
CV virus was isolated from a sick sheep and from
a healthy cow in a herd with reproductive prob-
lems (18). This virus also was isolated in Texas in
1988 from a sentinel sheep in pasture where an
outbreak of congenital defects had occurred in
1986 to 1987. These historical data suggest that
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be more widespread than has been recognized.
Experimental infections have provided further
evidence that CV virus causes embryonic death
and multiple congenital malformations of sheep
(19) and cattle (J. Edwards, pers. comm.). No
association of TEN virus and disease in livestock,
wild animals, or humans has been reported.  To
determine whether infection with selected Bun-
yamwera serogroup viruses, CV and TEN, is asso-
ciated with certain human congenital defects, a
serosurvey was done with serum samples from
mothers of children with microcephaly or macro-
cephaly, and the results were compared with those
from age- and location-matched controls.  The re-
sults, reported here, provide the first evidence
that these Bunyamwera serogroup viruses may be
etiologic agents of certain congenital defects of the
human central nervous system.
Two groups of 500 each human serum samples
were selected at random from an archival collec-
tion stored at the National Institutes of Health
(NIH), Bethesda, Maryland, and tested for neu-
tralizing antibody. These samples were part of a
collection of serum specimens obtained between
1959 and 1964, at delivery or post partum, (from
about 50,000 women enrolled under defined pro-
tocols in a prospective study of congenital rubella
syndrome. Specimens had been collected from all
pregnant women cared for at the particular insti-
tution or from women randomly selected by using
the last digit of their hospital registration number.
For a first series of tests, samples were selected
from 200 mothers of children with macrocephaly
(head size at least two standard deviations above
the mean) and from 50 mothers of children with
microcephaly (head size at least two standard
deviations below the mean). The initial specimen
from mothers with the respective defects was se-
lected for testing. An equal number of mothers of
babies without obvious central nervous system
defects were selected as controls, which were age-
(±2 years) and site-matched, were registered for
the study in the same month, and were of the same
race as mothers of children with either macro-
cephaly or microcephaly. Serum samples comprising
this first group had been collected from pregnant
women in Boston, Massachusetts (104), Provi-
dence, Rhode Island (20), New York, New York
(72), Philadelphia, Pennsylvania (36), Baltimore,
Maryland (38), Buffalo, New York (50), Minneapolis,
Minnesota (42), Charlottesville, Virginia (38),
Memphis, Tennessee (52), New Orleans, Louisi-
ana (36), and Portland, Oregon (12); these were
tested for neutralizing antibody to eight bun-
yaviruses (Table 1). 
An additional 500 samples were tested; 250
paired samples, selected as above, from the same
archival collection, two each from women in Bos-
ton (120), Buffalo (40), New Orleans (8), New York
City (46), Baltimore (8), Charlottesville (12), and
Minneapolis (16), including controls (selected as
above). These were tested for neutralizing anti-
body to CV virus only, to follow up on results of
tests with the first set of samples. One sample
from each of these women had been collected in the
first trimester of pregnancy, and the second had
been collected at least 3 months later. Serum speci-
mens were stored frozen at -20oC until they were
shipped on dry ice (-70
oC) to the Centers for Dis-
ease Control laboratory at Fort Collins, Colorado.
Twenty-nine of the first 500 serum specimens
tested contained neutralizing antibody to CV, 29
had antibody to TEN, 29 to Jamestown Canyon,
26 to La Crosse, nine to Lokern, and six to Button-
willow viruses. None had antibody to Main Drain
or Mermet virus. No significant differences were
observed in antibody prevalences to La Crosse,
Jamestown Canyon, Lokern, and Buttonwillow
viruses between mothers of microcephalic and
macrocephalic infants and age- and location-
matched controls (Table 1). Cases were not re-
viewed for other defects.
The prevalence of antibody to CV virus in moth-
ers of microcephalic infants was not significantly
different from the prevalence of such antibody in
their matched control, but the presence of anti-
body to CV virus in mothers was significantly
correlated with macrocephaly in their infants (c2,
d.f. = 1, n = 400, 4.797 p <0.05) (Table 1). 
None of the samples with neutralizing antibody
to CV or TEN virus (titers ranged from 10 to 80)
had IgM antibody. To determine whether there
were statistically significant differences between
prevalences of antibody to CV or TEN virus in
mothers of macrocephalic infants and in their age-
and site-matched controls, McNemar’s chi-square
was used. No significant difference was found for
the presence of antibody to CV virus (p >0.05), but
the presence of antibody to TEN virus (p < 0.05 or
antibody to either CV or TEN virus (p <0.02) was
related to the occurrence of macrocephaly in the
infants of these mothers (Table 2).
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CV and to TEN virus in women by hospital loca-
tion and birth outcome. When prevalence of anti-
body to CV or TEN virus in these women was
analyzed by location and birth outcome, no statis-
tically significant differences were determined
(comparative data not shown).
When the second set of 500 specimens (250
paired early- and late-pregnancy samples) was
tested, specimens from eight women had neutral-
izing antibody to CV virus. No diagnostically mean-
ingful change in titer was detected between six
sample pairs, but fourfold rises in titer were detected
in two others, (10 to 80,  <10 to 40), indicating recent
infections with CV virus or with a closely related
Bunyamwera virus group. Six of the eight women in
this group with antibody to CV virus delivered
macrocephalic infants, including the two (one in
New Orleans and one in New York City) whose
specimens showed rises in titer to CV virus.
These analyses provide the first evidence that
Bunyamwera serogroup viruses in North America
are associated with congenital defects in humans:
the occurrence of macrocephaly in infants was
positively correlated with antibody to CV virus.
Antibody to TEN virus and to either CV or TEN
virus correlated with microcephaly and with
macrocephaly. The presence of antibody to CV and
to TEN viruses corresponded with the known geo-
graphic distributions of these viruses within the
United States. Antibody to either of these viruses
in a woman living in an area where that virus is
not known to occur may reflect the close antigenic
relationships and considerable cross-reactivity of
these Bunyamwera serogroup viruses (22), differ-
ences between local virus strains and prototype
viruses, or travel to an area in which the virus does
occur (23). The two women with diagnostically
significant rises in antibody titer to CV virus (one
from New Orleans, where TEN virus has been
isolated, and one from New York, where CV virus
has been isolated) are, as far as we know, the first
two persons with documented rises in antibody to
a Bunyamwera serogroup virus in North America.
Whether either of them had an associated illness
could not be determined from the records. That
among all the women tested they were the only
ones with rises in antibody titer and that both gave
birth to macrocephalic infants is, at the least, a
fascinating coincidence. IgM antibody in human
infections caused by other bunyaviruses may not
persist for much more than a few months after
Table 1. Antibody to Cache Valley, Tensaw, La Crosse,
Jamestown Canyon, Lokern, or Buttonwillow viruses in moth-
ers of microcephalic or macrocephalic infants and matched
controls
Antibody to virus  Infant’s condition  c 
2(p)
Cache Valley Microcephaly  3.840 (0.05)
Macrocephaly 4.797 (<0.05)
Either 0.915 (>0.20)
Tensaw Microcephaly 4.891 (<0.05)
Macrocephaly 4.071  (<0.05)
Either 0.329 (>0.20)
Cache Valley or Tensaw Microcephaly 5.983 (<0.02)
Macrocephaly 4.806 (<0.05)
La Crosse Microcephaly 0.211 (>0.20)
Macrocephaly 1.481 (>0.20)
Jamestown Canyon Microcephaly 0.709 (>0.20)
Macrocephaly 0.037 (>0.20)
Lokern Microcephaly 1.010 (>0.20)
Macrocephaly 2.041 (>0.10)
Buttonwillow Microcephaly 2.041 (>0.10)
  Macrocephaly <0.001 (>0.20)
Bunyaviruses used for all tests were prototypes: (Bunyamwera
serogroup) CV (strain 6V-633), TEN (A9-171b), Lokern
(FMS-4332), Main Drain (BFS-5015), (California serogroup) La
Crosse (Original), Jamestown Canyon (61V-2235), (Simbu
serogroup) Buttonwillow (A-7956), and Mermet (AV-782).
Samples were tested for antibody by serum dilution-plaque
reduction neutralization (20). Briefly, diluted and heat-
inactivated (56
oC/30 min) serum was added to an equal
volume of virus containing approximately 200 plaque-forming
units (PFU), such that the final virus dilution was 100 PFU.
Fresh human serum at a final concentration of 8% was added
to all virus suspensions. Serum-virus mixtures were incubated
at 4
oC for 18 h, and 0.1-ml aliquots were dropped in the center
of Vero cultures grown in 6-well plastic plates. After a 45-min
period of adsorption, cells were overlaid with medium
containing 2% agar and further incubated for 70 to 75 h at
37
oC in 5% CO2-95% air. A second overlay, containing
medium, 2% agar, and 1:25,000 neutral red was then added,
and the plates again were incubated until plaques were
readable, usually 12 to 36 h later. A serum specimen was
considered positive when it reduced the number of plaques
90% relative to control titrations, which ranged from 80 to 150
plaques. Samples that were positive in a screening (1:10) test
were titrated for end-point, and the serum titer was taken as
the highest twofold dilution of serum that reduced the number
of plaques 90%.
Although a human positive control for detecting IgM antibody
by capture enzyme-linked immunosorbent assays was not
available, serum specimens were tested by a modification of a
published technique for detecting IgM antibody to California
serogroup viruses (21). Mouse or sheep serum samples
containing IgM antibody to CV virus or mouse serum with IgM
antibody to TEN virus served as positive and negative IgM
antibody controls. Statistical analyses were done by chi-square
or McNemar’s chi-square.
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in humans with antibody to Bunyamwera sero-
group viruses in North America. Therefore, the
absence of IgM antibody in specimens with neu-
tralizing antibody likely indicates that these infec-
tions were not acute, i.e., they occurred months
before the specimens were collected.
A fundamental problem in establishing a rela-
tionship between infection of mammals with CV
or TEN virus and attendant congenital anomalies
is the inherent inadequacy of controls. The pres-
ence of antibody in humans or other animals with
normal offspring does not necessarily argue
against the hypothesis that CV virus causes con-
genital defects in humans because infection could
have occurred before pregnancy. Additionally, even
if this virus can be an etiologic agent of congenital
anomalies, preexisting antibody to this virus could
provide immunity for the mother and protect the
fetus from viral infection. Thus, it cannot be deter-
mined with certainty whether the presence of
antibody to a virus is coincidental to, or a cause of,
the observed congenital anomalies.
Review of NIH records for this relatively small
set of samples suggested that macrocephaly oc-
curred somewhat more often when the first
trimester of pregnancy included the months April
and May for women living in New Orleans (4/16),
Memphis (5/16), and Charlottesville (3/12) and in
late summer-early autumn for women living in
Boston (6/49), Minneapolis (3/11), Portland (2/6),
and New York City (9/33). In each instance, these
periods coincide roughly with the appearance of
populations of Culiseta, Aedes, or Anopheles mos-
quitoes, the vectors of CV and TEN viruses. How-
ever, CV virus cannot be implicated in infections
in New Orleans because this virus is not known to
occur there, although TEN virus does.
The relatively small sample sizes in this study
allow statistical interpretation but do not provide
sufficient support to warrant statements as to the
biological significance of the findings; therefore,
we consider these data merely preliminary. Deter-
mining whether these data have merit awaits the
results of additional studies of mothers of children
with congenital defects and their offspring. More
extensive studies are also needed to investigate
the influence of gestational phase and fetal devel-
opment on congenital defects; establish relation-
ships between peak abundance of arthropod
vectors and first trimesters of pregnancies; se-
quence the genomes of CV and TEN virus strains
from various geographic areas and establish rela-
tionships between different gene sequences and
virulence in livestock; and develop diagnostic
capacity by using monoclonal antibodies, hybridi-
zation assays, polymerase chain reaction, and
Western blotting techniques.
Table 2. Presence of antibody to Cache Valley and Tensaw viruses in mothers of macrocephalic infants and in matched controls
Mothers of Antibody-positive Antibody-negative
macrocephalic infants No.  controls controls
Antibody  to  CV  virus  16       3    13
No  antibody  to  CV  virus 184       5   179
 McNemar’s  testa
Antibody  to  TEN  virus  15       1    14
No  antibody  to  TEN  virus 185       5   180
 McNemar’s  testb
Antibody  to  CV  or  TEN  virus  (or  both)  19       3    16
No  antibody  to  CV  or  TEN  virus 181       5   176
 McNemar’s  testc
 a (13-5)
2/18 = 3.556 (d.f. = 1), p > 0.05.   
b (14-5)
2/19 = 4.263 (d.f. = 1), p <0.05.  
c (16-5)
2/21= 5.762 (d.f. = 1), p <0.02.
Table 3. Antibody to Cache Valley and Tensaw viruses in
women, by location and birth outcome
    Antibody to CV virus          Antibody to TEN virus    
In women with In women with 
 macrocephalic In macrocephalic:   In
infants:: controls: infants:  controls:
Location no. (%) no. (%) no. (%)  no. (%)         
Boston 2/49 (4.1) 1/49 (2.0) 1/49 (2.0) 1/49 (2.0)
Providence 0/7 1/7 (14.3) 0/7 1/7 (14.3)
New York City 2/33 (6.1) 1/33 (3.0) 1/33 (3.0) 1/33 (3.0)
Philadelphia 0/15 2/15 (13.3) 1/15 (6.7) 2/15 (13.3)
Minneapolis 1/11 (9.1) 0/1 1/11 (9.1) 0/11 
Charlottesville 2/12 (16.7) 0/12 2/12 (16.7 0/12 
Memphis 6/16 (37.5) 3/16 (18.8) 5/16 (31.3) 1/16 (6.3)
New Orleans 1/16 (6.3) 0/1 2/16 (12.5) 0/16 
Portland 2/6 (33.3) 0/6 2/6 (33.3) 0/6 
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yaviridae cause congenital defects in naturally
and experimentally infected livestock, or may have
such a potential (24,25), it would be worthwhile to
continue investigations with domestic animals and
to develop laboratory models to assess the terato-
genic potential for humans of CV, TEN, and other
viruses of the family Bunyaviridae. 
It is also important to determine the roles of CV
and TEN viruses in inducing human congenital
defects and the relationships between prevalence
of antibody to CV and TEN viruses, prevalence of
congenital defects, and conception dates, all with
respect to local environmental conditions.
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